Scholars Central

OtherPublished 12 Jul 2016

Emerging therapies for pulmonary arterial hypertension: a review of recently completed and ongoing clinical trials

Authors: Amresh Raina, Raymond L Benza

Clinical Investigation

Volume 2 · Issue 5 · Pages 491–501

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Pulmonary arterial hypertension (PAH) is a rare, progressive disorder that leads to an inexorable rise in pulmonary vascular resistance, ultimately resulting in right ventricular failure and death if left untreated. Currently available pulmonary vasoremodeling therapy has significantly improved morbidity and mortality in PAH. However, 3-year mortality in PAH is still higher than in many other cardiovascular diseases. Recent and ongoing clinical trials in PAH have evaluated five major avenues of clinical investigation: trials of combination therapy using current US FDA-approved agents; trials of new forms or new delivery systems of existing agents; trials of newly developed agents that target novel steps in existing pathways implicated in the pathogenesis of PAH; trials of agents targeting new pathways that may play a role in PAH; and stem-cell and molecular therapy for PAH. This article reviews evidence for emerging therapies for PAH based on recently completed and ongoing clinical trials.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in Clinical Investigation.

All its articles

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalClinical Investigation
  • SubjectGeneral & Internal Medicine
  • BylineArticles whose byline prints “Amresh Raina”
  • BylineArticles whose byline prints “Raymond L Benza”